A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies

C. C. Lin, W. C. Su, C. J. Yen, C. H. Hsu, W. P. Su, K. H. Yeh, Y. S. Lu, A. L. Cheng, D. C.L. Huang, H. Fritsch, F. Voss, T. Taube, J. C.H. Yang

研究成果: Article同行評審

58 引文 斯高帕斯(Scopus)

指紋

深入研究「A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies」主題。共同形成了獨特的指紋。

Medicine & Life Sciences